Jaume Mora, Godfrey C. F. Chan, Daniel A. Morgenstern, Loredana Amoroso, Karsten Nysom, Jörg Faber, Arthur Wingerter, Melissa K. Bear, Alba Rubio-San-Simon, Blanca Martínez de Las Heras, Karen Tornøe, Maria Düring, Brian H. Kushner. "The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial." Nature Communications, 2025. doi:10.1038/s41467-025-56619-x